Data as of Dec 11
| -1.15 / -5.63%|
Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells and tumor bulk. The company primarily consisted of advancing its two clinical stage products: SL-401 and SL-701. The lead indication for SL-401, a biologic targeted therapy is acute myeloid leukemia. The lead indications for SL-701, a therapeutic cancer vaccine comprised of synthetic peptides that correspond to specific targets, called epitopes, on cancer stem cells and tumor bulk of brain cancer, are pediatric and adult brain cancer. It also develops a broad portfolio of preclinical small molecules and antibodies for a variety of solid and hematological cancer types. Stemline Therapeutics was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.
|Ivan Bergstein||Chairman, President, CEO, Secretary & Treasurer|
|Kenneth Hoberman||Chief Operating Officer|
|Thomas P. Cirrito||Vice President-Research & Development|
|Eric K. Rowinsky||Chief Medical Officer, Head-Research & Development|
|Michael Szarek||Head-Clinical & Regulatory Affairs|